UTHR8:00 AMUnited Therapeutics Corporation Announces Accelerated Share Repurchase Agreement for Remainder of $2.0 Billion Authorizationunither.com
UTHR8:00 AMUnited Therapeutics Corporation Announces FDA Acceptance of Supplemental New Drug Application for Nebulized Tyvaso® to Treat Idiopathic Pulmonary Fibrosisunither.com
UTHR8:00 AMUnited Therapeutics Corporation Announces Participation at Upcoming Investor Conferencesunither.com
UTHR8:00 AMUnited Therapeutics Presents Data at The European Society of Cardiology Congress 2026 and The European Respiratory Society International Congress 2026Presentation / Abstract • Phase 3ESC late-breaking oral presentation Sat, Aug 29, 2026, 11:00 AM CESTunither.com
UTHR8:00 AMUnited Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial Hypertensionunither.com
UTHR8:00 AMUnited Therapeutics Corporation Announces Full Enrollment of the TETON-PPF Study of Inhaled Treprostinil for the Treatment of Progressive Pulmonary FibrosisEnrollment • Phase 3Enrollment completion Mon, Aug 17, 2026unither.com
UTHR7:30 AMUnited Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Published in The LancetTrial Results • Phase 3unither.com
UTHR7:30 AMUnited Therapeutics Corporation Announces Appointment of Victor Dzau to its Board of Directorsunither.com
UTHR8:00 AMUnited Therapeutics Corporation to Report Second Quarter 2026 Financial Results Before Market Open on Wednesday, August 5, 2026unither.com
UTHR7:30 AMUnited Therapeutics Corporation Announces FDA Approval of the LungFX™ Device for Centralized Ex Vivo Lung Perfusionunither.com